Status:
NOT_YET_RECRUITING
The Feasibility of the OpiVenture Program for Clients Undergoing Opioid Agonist Therapy
Lead Sponsor:
Dalhousie University
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Direction 180 | Nova Scotia Mental Health and Addictions
Conditions:
Opioid Use Disorder
Polysubstance Addiction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The opioid crisis continues its devastating impact on Canada, with over 13,900 deaths recorded between 2016 and 2019. Dangerous prescription opioid usage persists, affecting 12.3% of Canadians in 2018...
Detailed Description
The opioid crisis continues to devastate individuals, families, and communities across Canada. In 2016-19, more than 13,900 opioid-related deaths occurred in Canada. Dangerous patterns of prescription...
Eligibility Criteria
Inclusion
- Currently enrolled in Opioid Agonist Therapy at one of the 4 partner clinics in Quebec and Atlantic Canada for 30 days
- ≥18 years of age Score at least one standard deviation (SD) above the population-specific norm on 1 of 4 personality traits on the Substance Use Risk Profile Scale (SURPS ) Ability to understand spoken English or French Ability to provide informed consent
Exclusion
- Those who are unable to provide informed consent and indicate severe cognitive impairment -measured by the Mini-Mental State Examination (MMSE), will be excluded.
Key Trial Info
Start Date :
October 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06211972
Start Date
October 15 2024
End Date
February 1 2026
Last Update
July 30 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.